18
Sep

Amid widespread safety concerns surrounding testosterone drugs, an FDA panel has recommended against Clarus Therapeutics’ oral treatment, dimming the future for the company’s sole product.

…read more

Source: FDA advisers shoot down Clarus’ pitch for a new low-T drug

    

0 No comments